Objective: Several pharmacological agents have been shown to produce 'physiological' or 'pathological' hypertrophy based on their functional characteristics. The aim of this study was to examine the features of cardiac hypertrophy induced by the selective b -adrenergic agonist, clenbuterol. Methods: Cardiac hypertrophy was induced in 7-week-old Sprague-Dawley rats by daily injections of 2 clenbuterol for 3 weeks. Thyroxine and isoproterenol were also used to produce cardiac hypertrophy to serve as positive controls for physiological and pathological hypertrophy, respectively. Left ventricular function was determined using an isolated rat heart preparation. Ventricular samples were used for morphological examination while interstitial collagen was measured using high-pressure liquid 2q Ž . Ž . chromatography. Expression of sarcoplasmic reticulum Ca -ATPase2a SERCA2a and phospholamban PLB were measured by dot blot analysis. Results: Clenbuterol treatment induced 26% left ventricular hypertrophy. These hearts demonstrated normal systolic Ž . isovolumic parameters and diastolic active relaxation and passive stiffness function. In addition, left ventricular concentration of collagen and morphology was normal as were the expression of SERCA2a and PLB mRNA. Conclusion: These results suggest that clenbuterol-induced hypertrophy is 'physiological' in terms of its function, extracellular structure and gene expression. q 1998 Elsevier Science B.V.
Introduction
Previous studies have shown that different stimuli induce cardiac hypertrophy in animals with specific funcw x tional, molecular and morphological features 1-6 . Based on these characteristics, cardiac hypertrophy has been described as either 'pathological' or 'physiological'. Pres-Ž . sure-overload left ventricular LV hypertrophy induces pathological hypertrophy with impairment in systolic function, myocardial relaxation and an increase in diastolic w x stiffness 1,2 . Abnormalities in diastolic relaxation and systolic function are thought to be due to the down regulation of intracellular calcium handling proteins including 2q Ž . sarcoplasmic reticulum Ca -ATPase2a SERCA2a and Ž . w x phospholamban PLB 7-9 . SERCA2a facilitates the transport of intracellular Ca 2q into the sarcoplasmic reticu-Ž . lum SR while phosphorylation of PLB increases the affinity of SERCA2a for Ca 2q . In addition, increase in interstitial collagen has been shown to account for the increase in diastolic stiffness in pathological hypertrophy w x 2,10 . In contrast, cardiac hypertrophy induced by thyroxine and swimming training has been shown to be physiow x logical with enhanced systolic function 4,11 and normal w x ventricular collagen content 12 . Furthermore, thyroxine treatment increases gene expression of SERCA2a while w x 2q downregulating that of PLB 13 thereby, increasing Ca transport into the SR.
There has been considerable interest in the effects of adrenergic agents in cardiac hypertrophy, as endogenous catecholamines are known to be involved in both cardiow x vascular conditioning with exercise 14 and hypertrophy Time for primary review 31 days.
at Pennsylvania State University on February 22, 2013 http://cardiovascres.oxfordjournals.org/ Downloaded from ( )w x 15 . The characteristics of cardiac hypertrophy by iso-Ž . proterenol b -and b -agonist have been well described 1 2 and been shown to be similar to that seen with pressurew x overload 5,6 . Clenbuterol, a selective b -adrenergic agent, 2 has also been shown to induce an increase in the mass of the rat heart, although to date there has been little known w x about the pathophysiology of such hypertrophy 16-19 . We have recently reported that clenbuterol induces cardiac hypertrophy in the rat with no changes in gene Ž expression indicative of pathological hypertrophy absence of skeletal actin and predominantly a-cardiac myosin heavy
. w x chain isoform 20 . However, LV function in clenbuterolinduced cardiac hypertrophy has not been previously investigated. The purpose of this study was to determine its LV function, collagen concentration and morphology. In addition, the mRNA expression of intracellular calcium handling proteins, SERCA2a and PLB, which are known to be important determinants of LV function in the rat, were measured.
Methods

Animals and treatment regimen
The animals were treated in accordance with the Guide for the Care and Use of Laboratory Animals published by Ž the US National Institutes of Health NIH publication no.
. 85-23, revised 1985 . Two sets of rats were prepared for: Ž . a measurement of LV function and extracellular collagen Ž . and histology, or b molecular analysis. Fifty-five 7-week-Ž . old male Sprague-Dawley Harlan, UK rats weighing 200-225 g were fed normal rat chow and water ad libitum over a 3-week experimental period. Eight experimental Ž . Ž . groups were studied: Groups I n s 8 and V n s 6 were Ž . used as controls and injected subcutaneously s.c. with 0.5 Ž . Ž . ml of saline vehicle once daily. Groups II n s 8 and VI Ž . Ž n s 8 were injected s.c. with clenbuterol a gift from . Boehringer Ingelheim, UK once daily at a dose of 2 w x Ž . Ž . mgrg body weight 20 . Groups III n s 8 and VII n s 8 were injected intraperitoneally with 3.5 mgrkg of DL-Ž . Ž . thyroxine Sigma, UK once daily. Groups IV n s 6 and Ž . VIII n s 5 received once daily s.c. injections of isoprote-Ž . renol 1 mgrkg for the last 2 weeks of the experimental period. Thyroxine and isoproterenol groups served as positive controls for physiological and pathological cardiac hypertrophy. The dose and mode of administration of these drugs were based on previous work and that reported in w x the literature 5,20,21 .
Perfusion technique and eÕaluation of Õentricular function
Perfusion technique
Groups I, II, III and IV were sacrificed for functional experiments. LV function was measured using an isolated Ž . rat heart preparation Langendorff . At the end of the experimental period, animals were administered an intraperitoneal injection of 0.3-0. 
Ž
. was similar in all groups data not shown . Isovolumic LV pressure measurements were recorded with the balloon volume fixed at an end-diastolic pressure of 10 mmHg while pressure-volume measurements were recorded during increments of 0.02 ml of balloon volume. Two sets of pressure-volume measurements were recorded for each Ž . heart and reproducible results "10% used for analysis. Unstable preparations were also discarded and this resulted Ž . in the use of 30 of 38 preparations 79% .
LV function analysis
Systolic function was determined from the developed Ž . systolicy diastolic pressure normalised to the weight of the left ventricle and the ratio of the maximal rate of pressure increment to the instantaneous pressure Ž . Ž . dPrdt rP at an end-diastolic pressure EDP of 10 max mmHg. Diastolic function was determined from dPrdt min at an EDP of 10 mmHg, a measure of active relaxation and Ž . the passive stiffness of the intact ventricle chamber and Ž . myocardium tissue . Chamber stiffness was analysed from Ž . the end-diastolic pressure-volume relationship dPrdV . In order to correct for differences in LV mass and size of different hearts, the exponential stiffness coefficient was Ž 2 . Ž determined from the stress s , g per cm and strain´, . % for the midwall of the LV assuming a spherical geomew x try 2 :
Ž . 
The diastolic pressure-volume and diastolic stressstrain curves were fitted to mono-exponential relations:
w BŽEDVyV o. x w DŽ´. x EDP s A e y 1 and s s C e y 1 , respectively, where A, B, C and D are regression constants of the respective equations. By logarithmic transformation, each set of data was converted to a linear relationship and slope values used for comparison. The slope of the stressstrain relationship represents the exponential stiffness constant.
Collagen concentration and morphology
LV tissue from animals in the functional experiments Ž . groups I, II, III and IV were used for determination of collagen concentration quantified from the concentration of hydroxyproline by high pressure liquid chromatography Ž .w x HPLC 22 . Values were reported as nanograms of colla-Ž . gen assuming a hydroxyproline content of 12.2% wrw w x Ž 23 . To identify any changes in morphology myocyte . necrosis, inflammatory cell infiltration , a coronal section was obtained at the equator of the LV from which 5-mm paraffin sections were prepared and stained with haematoxylin and eosin.
Analysis of mRNA
Animals were sacrificed at 3 weeks for molecular analysis. Samples were snap frozen in liquid nitrogen and stored at y808C. RNA was extracted from tissue samples by the guanidium thiocyanate-phenol-chloroform techw x nique 24 .
Relative abundance of specific mRNAs was measured by dot blotting as described using 32 P-labelled cDNA Ž probe complementary to ANF plasmid kindly provided by
. w x w x w x K. Khowlton, San Diego 20 , SERCA2a 25 , PLB 26 and a 32 P-endlabelled oligonucleotide complementary to 18S ribosomal RNA. The resultant dots were quantified by densitometry. Values for ANF, SERCA2a and PLB were standardised to the respective values for 18S. 'Hot' reverse Ž . transcriptase-polymerase chain reaction RT-PCR analysis of MHC Iso-mRNAs was also performed as previously w x described 20 by PCR amplification using a forward and Ž . reverse primer identical to sequences for a-and b-MHC w 32 x and an end-labelled P forward primer, TaqI DNA Polymerase, 20 mM dNTPs. The MHC iso-RNAs were distinguished by digestion of 25 ml of PCR products with Ž Tru9I digestion. The fragments a-MHC 309 base pairs, . b-MHC 259 and 50 base pairs were separated on an 8% SDS-polyacrylamide gel. The gel was dried and exposed to X-ray film at y708C. The resultant bands on the autoradiogram were quantified by densitometry and the ratio of the b-MHC isoform to the respective quantity of total MHC isoforms.
Determination of mass data
Hearts were blot dried and the great vessels trimmed away before weighing. The atria were excised and the right Ž . and left ventricle including interventricular septum separated before weighing. LV mass index was calculated from the ratio of the left ventricular weight to left tibial length. As clenbuterol is known to cause skeletal muscle hypertrophy and catabolism of adipose tissue, the left gastrocne-Ž . mius plantaris-soleus GPS and the left perinephric fat pad were removed and weighed as previously described w x 20 .
Statistical analyses
All group data are presented as mean " s.e.m. and Ž . compared by analysis of variance ANOVA with Bonferroni bounds and two-tailed Student's t-test for unpaired data where appropriate. Results were considered significant when P -0.05.
Results
Effects of clenbuterol on mass data
The mean body weight of clenbuterol treated rats were significantly greater than the control, isoproterenol and thyroxine groups by 15%, 13.9% and 13.1%, respectively Ž . Ž . P -0.01 Table 1 . This increase was predominantly attributable to the growth of skeletal muscle mass as evidenced by an increase in the left GPS muscle mass which was significantly increased compared to control, isoproterenol and thyroxine groups by 33.5%, 26.0% and Ž . 31.7%, respectively Table 1 . These findings in addition Ž . to that of a significant decrease 41% in perinephric fat in the clenbuterol group to the control group is consistent with clenbuterol's known repartitioning effect.
The effects of pharmacological agents on the LV mass index are shown in Fig. 1 . Clenbuterol significantly increased the LV mass index by 26.3 " 2.9% compared to controls. This confirms our previous findings and those of others of a significant increase in heart mass with clen- buterol treatment which in our study was similar to that Ž . induced by thyroxine 22.2 " 1.6% , although isoproterenol treatment produced the greatest degree of hypertro-Ž . phy 42.8 " 3.8% .
The effect of all three agents were not chamber-specific, and global hypertrophy was seen as demonstrated by the LVrRV ratios: control 5.19 " 0.18, clenbuterol 5.00 " 0.19, thyroxine 5.36 " 0.17 and isoproterenol 4.49 " 0.19 Ž . all treated groups vs. control, P ) 0.05 .
Left Õentricular function
The normalised developed pressure and dPrdt rP max were similar in the clenbuterol and thyroxine group com-Ž . pared to that of controls Table 2 . This is in contrast to the isoproterenol group, where dPrdt rP was significantly max reduced although normalised developed pressure was normal. dPrdt in the clenbuterol group was also similar to min Ž . that of the control and thyroxine groups Table 2 . Ventric-Ž . ular stiffness dPrdV as analysed from the EDP-volume relationship demonstrated normal stiffness in the clenbuterol and thyroxine groups in contrast to that of the Ž isoproterenol group which was significantly increased . 2a,b . The exponential stiffness coefficient was also normal in the clenbuterol and thyroxine groups unlike that in Ž . the isoproterenol group Fig. 2b . Fig. 3 demonstrates the LV collagen concentration between the groups. Clenbuterol-induced cardiac hypertrophy was associated with no significant differences in collagen concentration to the control group. This was similar to that with thyroxine treatment but was in contrast to that with isoproterenol which had a 65% increase in collagen. Histological examination of the clenbuterol and thyroxine groups Ž . further demonstrated normal morphology Fig. 4b ,c unlike that seen in the isoproterenol samples which had patchy Ž myocyte necrosis inflammatory cell infiltrate, disruption . of myocytes and fibrosis replacing myocardial tissue within the subendocardium and interventricular septum Ž . diastolic passive properties found in clenbuterol-induced cardiac hypertrophy.
Collagen concentration and morphology
RNA analyses in the heart
As a marker of myocardial hypertrophy, the LV expression of ANF was measured and found to be increased by Ž . 2-fold in clenbuterol-treated animals Table 3 . Thyroxineand isoproterenol-treated rats had higher expressions of Ž . ventricular ANF 3-and 8-fold, respectively .
The ratios of b-MHC to total MHC mRNA expression in clenbuterol and thyroxine groups were similar to that of the control group. The isoproterenol group showed a mild shift towards the b-MHC isoform compared to controls Ž . Ž . P ) 0.05 Table 3 . The difference in proportion of b-MHC was, however, 2-fold between the clenbuterol and Ž . isoproterenol group P -0.05 . Table 3 shows the expression of SERCA2a and PLB mRNA. Clenbuterol-treated hearts had normal expression of SERCA2a while thyroxine-treatment led to a 50% Ž . increase in SERCA2a expression P s 0.19 . There were no significant changes in SERCA2a expression in the isoproterenol group, although 2 of 5 hearts expressed only 50% of the mean control level. PLB mRNA expression was unchanged in all treated groups relative to controls.
Ž .
Ž . Fig. 4 . Representative LV sections stained with haematoxylin and eosin demonstrating morphology in clenbuterol-b and thyroxine-treated c hearts to be Ž . Ž . similar to that of controls a . In contrast, isoproterenol-treated hearts d showed characteristic myocyte necrosis with collagen replacement in these areas. Scale bar s 0.25 mm. 
Discussion
Previous studies have shown that different adrenergic agonists induce specific types of hypertrophy through difw x ferent mechanisms 15 . The adrenergic agents norepinephrine and isoproterenol have been shown to induce pathow x logical changes 5,6 . We hypothesised that the selective b -agonist, clenbuterol, may induce physiological hyper-2 trophy in the rat based on the gene expression of its w x ventricular MHC isoforms 20 . The present study has further demonstrated normal left ventricular function, morphology and collagen concentration, as well as mRNA expression of SERCA2a and PLB in clenbuterol-induced cardiac hypertrophy in rats.
The dose of 2 mgrg body weight used in this study was w x based on our preliminary work 20 . This dose is large in comparison to that which has been reported in human use w x 27 , although no formal clinical dose-response trials have been performed. There have also been no scientific reports of cardiac hypertrophy following clenbuterol treatment in humans.
Ž . In rats, however, the modest increase in LV mass 26% by clenbuterol as observed in this study is consistent with w x that previously reported by us 20 and similar to that seen with thyroxine. Isovolumic systolic parameters in clenbuterol-induced hypertrophy were normal, which is unlike the supraphysiological systolic function observed by others w x with thyroxine-induced hypertrophy 28 . However, this may be explained by differences in techniques used to measure contractile function, as thyroxine-treated hearts in our experiments also demonstrated equal performance to the controls. It was, however, important to find normal systolic function in clenbuterol-induced hypertrophy, as systolic function in cardiac hypertrophy induced by other adrenergic agents such as isoproterenol may be impaired w x as demonstrated in this study, and by others 29 . The reduced speed in contractility of isoproterenol-induced hypertrophy may be accounted for by the mild increase in proportion of b-MHC isoform. In small animals where the predominant MHC isoform is the a-isoform, a switch to the b-MHC isoform is often seen in pathological hypertrophy and results in a reduced maximal shortening velocity w x w x 30 . As previously demonstrated 20 , the proportion of a-MHC isoform was found to be normal in clenbuteroltreated hearts.
Pathological cardiac hypertrophy is also associated with diastolic dysfunction detected either as an increase in w x w x relaxation times 1 or passive stiffness 2,10 . The latter was demonstrated in isoproterenol-treated hearts in our study but, in contrast, clenbuterol-treated hearts demonstrated normal dPrdt and passive stiffness similar to min that found with thyroxine. The finding of normal active relaxation is consistent with the normal expression of SERCA2a and PLB mRNA found in the clenbuterol-and thyroxine-treated hearts. The normal mRNA expression of SERCA2a and PLB in these ventricles is similar to that w x described in swimming rats 31 . In the case of thyroxine, however, our findings were disparate to other reports of thyroxine-induced hypertrophy which have shown an increase in SERCA2a and a decrease in PLB mRNA expresw x sion 13 . This may be accounted for by the use of different dose regimens or animal model. At the time points studied, expression of SERCA2a and PLB mRNA were not significantly reduced in the isoproterenol group, which is consistent with results found by Boluyt et al. w x when isoproterenol was administered for long periods 6 . This may be related to a downregulation of b-adrenergic receptors, and would also explain why a greater change in MHC isoform was not seen in the isoproterenol group.
Significantly, the increase in LV mass with clenbuterol was without a concomitant increase in extracellular collagen. This has important functional consequences, as increases in extracellular collagen are responsible for increases in passive diastolic stiffness seen in pathological w x hypertrophy such as that with isoproterenol 2,10 . This increase in collagen may also account for the reduced speed of contraction observed with isoproterenol. Another important feature of clenbuterol-induced hypertrophy was the normal morphology observed which is in contradistinction to the characteristic myocyte death seen with isoprotew x renol 5 .
The mechanism of myocardial growth with clenbuterol is poorly understood. We have previously suggested this to be a compensatory hypertrophy secondary to an increased haemodynamic demand from a greater skeletal muscle mass similar to that seen with sympathetically-mediated w x effects of cardiovascular conditioning 20 . Clenbuterol may act directly on b -receptors which may be in the and isoproterenol. It has also been suggested that clenbuterol's action on cardiac muscle may be independent of that on skeletal muscle by the fact that cyclo-oxygenase inhibitors have been shown to selectively inhibit clenbuterol's actions on the myocardium without antagonising w x skeletal muscle growth 19 . Further work to elucidate the mechanism of clenbuterol should involve investigating the transduction pathways including the measurement of the Ž . proto-oncogenes c-fos, c-jun and signalling pathways such as the G-proteins and mitogen-activated protein kinase cascade.
The finding that clenbuterol, a selective b -adrenergic ( )phy extends our understanding of the different mechanisms involved in the induction of hypertrophy and may have important clinical implications. Experimentally, growth hormone and its local effector, insulin-like growth factor, has been shown to enhance ventricular function in normal w x and failing hearts 33,34 . Although one of the current aims of medical therapy in heart failure is the regression of cardiac hypertrophy, it has been suggested that the induction of physiological hypertrophy may decrease wall stress and improve ventricular function in patients with heart w x failure 35 . Our findings suggest that clenbuterol may also be a candidate for inducing physiological hypertrophy and could be used in such a setting. Furthermore, unlike growth hormone and thyroxine, it is devoid of major systemic side effects.
In conclusion, it would appear that unlike cardiac hypertrophy induced by other adrenergic agents, clenbuterolinduced cardiac hypertrophy is not associated with pathological changes and is physiological in terms of function, structure and gene expression. Further studies are needed to investigate its effects on experimental heart disease Ž . cardiac hypertrophy and failure and its possible role in clinical practice.
